Clinical trajectories and biomarkers for weight variability in early Parkinson's disease.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
02 Aug 2022
02 Aug 2022
Historique:
received:
03
02
2022
accepted:
13
07
2022
entrez:
2
8
2022
pubmed:
3
8
2022
medline:
3
8
2022
Statut:
epublish
Résumé
Unexplained weight changes that occur in Parkinson's disease (PD), are often neglected and remain a poorly understood non-motor feature in patients with PD. A specific 'Park-weight' phenotype with low body weight has been described, and our aim was to evaluate the clinical and prognostic trajectories and biomarkers of weight variability in PD. We evaluated body weight-related biomarkers in 405 de novo PD patients and 187 healthy controls (HC) over a 5-year follow-up period from the PPMI database. Body-weight variability was defined as intra-individual variability in body weight between visits. PD patients were categorized as weight losers, gainers, or patients with stable weight. The differential progression of motor and non-motor clinical variables between groups was explored using linear mixed-effects models. Finally, we estimated longitudinal changes in weight as a function of baseline and longitudinal striatal presynaptic dopaminergic transporter imaging. PD patients presented a greater weight variability compared to HC (p = 0.003). Patients who developed weight loss had lower CSF amyloid-beta 1-42 (p = 0.009) at baseline. In addition, patients with weight loss showed a faster cognitive decline (p = 0.001), whereas patients with weight gain showed a slower motor progression (p = 0.001), compared to patients with stable weight. Baseline right striatal denervation was a predictor of weight variability in both PD patients and HC (p < 0.001). Similarly, weight variability in PD patients was associated with the progression of right striatal denervation (p < 0.001). Weight variability and specifically weight loss are more frequent in PD compared to HC, and are associated with specific motor, non-motor and cognitive progression patterns. A greater CSF amyloid burden was present at baseline in patients with subsequent weight loss. Presynaptic dopaminergic imaging in the right striatum may serve as a predictor of future weight changes in PD and HC.
Identifiants
pubmed: 35918350
doi: 10.1038/s41531-022-00362-3
pii: 10.1038/s41531-022-00362-3
pmc: PMC9345874
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95Informations de copyright
© 2022. The Author(s).
Références
Am J Epidemiol. 2008 Apr 1;167(7):831-8
pubmed: 18326873
Acta Neurol Scand. 2000 Feb;101(2):79-84
pubmed: 10685852
South Med J. 1992 Apr;85(4):351-4
pubmed: 1566133
Lancet Neurol. 2011 Mar;10(3):230-40
pubmed: 21317042
Parkinsonism Relat Disord. 2012 Sep;18(8):964-70
pubmed: 22682755
Front Aging Neurosci. 2018 Jan 19;10:1
pubmed: 29403371
Med J Aust. 2018 May 21;208(9):404-409
pubmed: 29764353
Neurology. 2010 Sep 21;75(12):1055-61
pubmed: 20720189
J Am Diet Assoc. 1995 Sep;95(9):979-83
pubmed: 7657912
Mov Disord. 2016 Aug;31(8):1095-102
pubmed: 26861861
J Am Geriatr Soc. 2008 Jan;56(1):111-6
pubmed: 18028342
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S41-6
pubmed: 26459660
Neurology. 2006 Dec 12;67(11):1955-9
pubmed: 17159100
Arch Gerontol Geriatr. 2012 Jul-Aug;55(1):70-2
pubmed: 21763014
J Neural Transm (Vienna). 2019 Jun;126(6):723-729
pubmed: 31102003
Exp Neurobiol. 2015 Mar;24(1):90-4
pubmed: 25792873
Acta Neurol Scand. 2017 May;135(5):560-567
pubmed: 27357472
Am J Epidemiol. 2007 Nov 15;166(10):1186-90
pubmed: 17709328
PLoS One. 2015 May 04;10(5):e0124541
pubmed: 25938478
N Engl J Med. 2017 Apr 6;376(14):1332-1340
pubmed: 28379800
Neurology. 2007 Jun 12;68(24):2156; author reply 2156-7
pubmed: 17562841
Eur J Neurol. 2009 Aug;16(8):895-901
pubmed: 19374662
Brain Stimul. 2013 Nov;6(6):845-55
pubmed: 23849716
Ann Neurol. 2003 May;53(5):676-9
pubmed: 12731005
Eur J Clin Nutr. 2003 Apr;57(4):543-7
pubmed: 12700615
Eur J Clin Nutr. 1992 Dec;46(12):879-84
pubmed: 1483417
Oncotarget. 2017 Oct 31;8(62):104706-104716
pubmed: 29285207
Neurodegener Dis Manag. 2014;4(4):309-16
pubmed: 25313987
Sci Rep. 2015 Jul 16;5:12144
pubmed: 26179594
JAMA Neurol. 2016 Mar;73(3):321-8
pubmed: 26751506
Parkinsonism Relat Disord. 2018 Jun;51:67-72
pubmed: 29510907
J Parkinsons Dis. 2011;1(2):197-203
pubmed: 23934921
Clin Auton Res. 1992 Jun;2(3):153-7
pubmed: 1498561
Nature. 2006 Sep 21;443(7109):289-95
pubmed: 16988703
Alzheimer Dis Assoc Disord. 2014 Jan-Mar;28(1):36-43
pubmed: 24126214
Brain. 2017 Jul 1;140(7):1959-1976
pubmed: 28549077
Front Neurol. 2014 Jun 02;5:84
pubmed: 24917848
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Neurology. 2017 Nov 28;89(22):2254-2261
pubmed: 29079685
Handb Clin Neurol. 2003;79:249-61
pubmed: 18808799
Physiol Rev. 2007 Jan;87(1):315-424
pubmed: 17237348
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477
pubmed: 30564614
Neurology. 2011 Nov 22;77(21):1913-20
pubmed: 22105948
Rheumatology (Oxford). 2010 Dec;49(12):2391-9
pubmed: 20805117
Synapse. 2002 Jun 1;44(3):175-80
pubmed: 11954049
J Parkinsons Dis. 2020;10(3):1003-1010
pubmed: 32444561
Mov Disord. 2021 Jul;36(7):1617-1623
pubmed: 33615545
N Engl J Med. 2003 Nov 13;349(20):1925-34
pubmed: 14614167
Arch Neurol. 2010 May;67(5):589-95
pubmed: 20457959
Acta Neurol Scand. 2004 Sep;110(3):180-7
pubmed: 15285776
Arch Neurol. 2005 Jan;62(1):55-60
pubmed: 15642850